Antigen-specific T cell responses in autoimmune diabetes

Front Immunol. 2024 Aug 15:15:1440045. doi: 10.3389/fimmu.2024.1440045. eCollection 2024.

Abstract

Autoimmune diabetes is a disease characterized by the selective destruction of insulin-secreting β-cells of the endocrine pancreas by islet-reactive T cells. Autoimmune disease requires a complex interplay between host genetic factors and environmental triggers that promote the activation of such antigen-specific T lymphocyte responses. Given the critical involvement of self-reactive T lymphocyte in diabetes pathogenesis, understanding how these T lymphocyte populations contribute to disease is essential to develop targeted therapeutics. To this end, several key antigenic T lymphocyte epitopes have been identified and studied to understand their contributions to disease with the aim of developing effective treatment approaches for translation to the clinical setting. In this review, we discuss the role of pathogenic islet-specific T lymphocyte responses in autoimmune diabetes, the mechanisms and cell types governing autoantigen presentation, and therapeutic strategies targeting such T lymphocyte responses for the amelioration of disease.

Keywords: T cells; antigen specific therapy; autoantigens; autoimmune diabetes; hybrid insulin peptides.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigen Presentation / immunology
  • Autoantigens* / immunology
  • Autoimmunity
  • Diabetes Mellitus, Type 1* / immunology
  • Epitopes, T-Lymphocyte / immunology
  • Humans
  • Insulin-Secreting Cells / immunology
  • Lymphocyte Activation / immunology
  • T-Lymphocytes* / immunology

Substances

  • Autoantigens
  • Epitopes, T-Lymphocyte

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The authors for this work were supported by the National Institutes of Health (NIH) R01 AI106791 (to BF), R01 AI156276 (to BF), P01AI35296 (to BF) and T32 AI007313 (to AD), The Leona M. and Harry B. Helmsley Charitable Trust (G-2303-06775 and G-2405-06927 to BF), the Minnesota Lions Diabetes Foundation and University of Minnesota Foundation Fund 11724 (Diabetes Cure Research Using Immune Regulation and Tolerance).